PubMed · 2017 · 20 citations · 35 references
MedicineCardiologyPharmacologyCellular MetabolismMitochondrial BiologyPreventive CardiologyCardiovascular Molecular PhysiologyCoronary Artery DiseaseEndothelial DysfunctionIschemic Heart DiseaseMicrocirculatory DysfunctionMitochondrial DysfunctionCardiac Mitochondrial FunctionGlycogen Synthase Kinase 3 RegulationGlycogen Synthase Kinase 3 SignalingMechanisms Of Cardiac InjuryMitochondrial Permeability Transition Pore SignalingMyocardial Ischemia MarkersMyocardial Ischemia-reperfusion InjuryProstaglandin Pharmacology
Prostaglandin E1 (PGE1) is used as a pretreatment for ischemia reperfusion injury in many biological systems. However, its value as a pretreatment for coronary microembolization (CME) is unknown. The goal of this study was to determine whether PGE1 would protect against CME. In a CME rat model, we observed microthrombi and early myocardial ischemia, with endothelium appearing exfoliated and mitochondria having irregular morphology and decreased internal complexity. The level of fibrinogen-like protein 2 prothrombinase was increased and superoxide dismutase and catalase levels were decreased. Moreover, mitochondria copy number and mitochondrial permeability transition pore (mPTP) opening were increased. Pretreatment with PGE1 (1 or 2 μg/kg) significantly improved these cardiological deficits, acting via the glycogen synthase kinase 3β (GSK-3β)-mPTP pathway. Unexpectedly, the phosphorylation of Akt at Ser473 decreased in the PGE1 at high dose. Overall, our findings suggested an important role for PGE1 in pretreatment of coronary microvascular dysfunction.
35
Coronary Microvascular Dysfunction
Paolo G. Camici, Filippo Crea · New England Journal of Medicine · 2007 · 1.6K citations